Pharmamarketeer

Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no

It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new offer comes in at €28 per share and is 14% higher than the one the company made on 22 December – a bid which Ablynx rejected. The deal also included an additional €2.50 per share dependent on specific research portfolio conditions.

Reageer

Medhc-fases-banner
Advertentie(s)